Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)
- Conditions
- Neoplasms, Breast
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 86
- Registration Number
- NCT00388076
- Locations
- 🇺🇸
GSK Investigational Site, Nashville, Tennessee, United States
Study To Assess Long Term Safety Of Pazopanib
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 188
- Registration Number
- NCT00387205
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom
A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT00370513
- Locations
- 🇨🇳
GSK Investigational Site, Taipei, Taiwan
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung CancerLung Cancer, Non-Small Cell
- Interventions
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2012-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT00367679
- Locations
- 🇪🇸
GSK Investigational Site, Barcelona, Spain
A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT00363194
- Locations
- 🇺🇸
GSK Investigational Site, Detroit, Michigan, United States
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT00358384
- Locations
- 🇫🇷
GSK Investigational Site, Paris, France
Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma
- First Posted Date
- 2006-07-11
- Last Posted Date
- 2013-04-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 75
- Registration Number
- NCT00350727
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
- Conditions
- Neoplasms, Breast
- Interventions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 189
- Registration Number
- NCT00347919
- Locations
- 🇬🇧
GSK Investigational Site, Plymouth, United Kingdom
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
- First Posted Date
- 2006-06-07
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 435
- Registration Number
- NCT00334282
- Locations
- 🇬🇧
GSK Investigational Site, Swansea, United Kingdom
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
- Conditions
- Sarcoma, Soft Tissue
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 148
- Registration Number
- NCT00297258
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.